In a seemingly endless war on cancer, the best weapon remains early detection, according to Graham Lidgard, senior vice president of R&D at Exact Sciences Corp. For Lidgard, and the rest of the team at the Madison, Wisc.-based molecular diagnostics maker, the battlefield is colorectal cancer, 1 of the most common, and deadliest, cancers in […]
The U.S. Food and Drug Administration today approved Cologuard, the first stool-based colorectal screening test that detects the presence of red blood cells and DNA mutations that may indicate the presence of certain kinds of abnormal growths that may be cancers such as colon cancer or precursors to cancer.
MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past couple days:
The federal Securities & Exchange Commission charged a Baltimore business consultant and his uncle in Cleveland of an insider trading scheme that netted the pair more than $600,000.
Exact Sciences Corp. (NSDQ:EXAS) filed a shelf registration statement for the sale of up to $150 million in equity, debt and warrants, according to the federal Securities & Exchange Commission.
In a press release, the Madison, Wis.-based molecular diagnostics developer said it does not have immediate plans to offer the securites, but wants to keep its options open.
Exact Sciences Corp.’s (NSDQ:EXAS) net losses for its 2010 second quarter were almost double the company’s revenues, but still less than during the same period last year.
The company reported a net loss of $2.5 million, or 6 cents per diluted share, on revenues of $1.3 million during the three months ended June 30. Those results compare with a net loss of $2.4 million, or 8 cents per diluted share, on sales of $1.3 million during Q2 2009.
Exact Sciences Corp. (NSDQ:EXAS) inked a licensing deal with Belgium-based OncoMethylome Sciences for that company’s DNA methylation biomarkers.
The Madison, Wis.-based company gained exclusive worldwide rights for up to two of OncoMethylome’s biomarkers utilized in its stool-based detection of colorectal cancer, the companies said.
Exact Sciences Corp. (NSDQ:EXAS) posted fourth-quarter sales of $1.2 million for the three months ended Dec. 31, 2009, compared with negative revenues of $109,000 during the same period in 2008. Net losses narrowed 13.9 percent to $1.8 million, compared with $2.1 million during Q4 2008:
Quest Diagnostics Inc. (NYSE:DGX) introduced a new blood test with the potential to identify colorectal cancer by detecting chemical changes in specific strands of genetic material.
Quest Diagnostics plans to market its new ColoVantage test as a supplement to other screening tools such as colonoscopy and fecal occult blood tests. Company officials said in prepared remarks that while ColoVantage has not yet been clinically validated, they hope the relative ease of a blood test would convince individuals who previously have passed on more invasive tests to be screened.